Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

NCT00552227 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: ruboxistaurin
OTHER: placebo

Sponsor

Chromaderm, Inc.